Atara Biotherapeutics (NASDAQ:ATRA) just reported results for the second quarter of 2024.
- Atara Biotherapeutics reported earnings per share of -$3.10. This was below the analyst estimate for EPS of -$1.56.
- The company reported revenue of $28.64 million.
- This was 28.38% worse than the analyst estimate for revenue of $39.99 million.